These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35734243)

  • 21. Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis.
    Mantravadi S; George M; Brensinger C; Du M; Baker JF; Ogdie A
    BMC Rheumatol; 2020; 4():39. PubMed ID: 32905192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis.
    Khraishi M; Millson B; Woolcott J; Jones H; Marshall L; Ruperto N
    Pediatr Rheumatol Online J; 2019 Sep; 17(1):64. PubMed ID: 31500631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis.
    Ogdie A; Maksabedian Hernandez EJ; Shaw Y; Stolshek B; Michaud K
    ACR Open Rheumatol; 2022 Nov; 4(11):935-941. PubMed ID: 35971643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids.
    Curtis JR; Xie F; Yang S; Bernatsky S; Chen L; Yun H; Winthrop K
    Arthritis Care Res (Hoboken); 2019 Sep; 71(9):1249-1254. PubMed ID: 30295428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
    Lie E; van der Heijde D; Uhlig T; Heiberg MS; Koldingsnes W; Rødevand E; Kaufmann C; Mikkelsen K; Kvien TK
    Ann Rheum Dis; 2010 Apr; 69(4):671-6. PubMed ID: 19740904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pain Medication and Corticosteroid Use in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis in the United States: A Retrospective Observational Study.
    Hunter T; Nguyen C; Birt J; Smith J; Shan M; Tan H; Lisse J; Isenberg K
    Rheumatol Ther; 2021 Sep; 8(3):1371-1382. PubMed ID: 34312825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment Persistence and Adherence Among Patients With Psoriatic Arthritis Who Initiated Targeted Immune Modulators in the US: A Retrospective Cohort Study.
    Walsh JA; Cai Q; Lin I; Pericone CD; Chakravarty SD
    Adv Ther; 2021 May; 38(5):2353-2364. PubMed ID: 33759081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB; von Kempis J; Haile SR; Schiff MH
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry.
    Gottlieb AB; Merola JF; Cirulli J; Williams CC; Linowski GJ; Paris M; Litman HJ; Guo N; Emeanuru K; McLean RR; Cronin A; Strober B
    Dermatol Ther (Heidelb); 2021 Feb; 11(1):253-263. PubMed ID: 33475970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Should All Patients Trial Subcutaneous Methotrexate Prior to Commencing Biologic Therapy? A Real World Study.
    Mirza A; Nisar MK
    Mediterr J Rheumatol; 2024 Mar; 35(1):115-122. PubMed ID: 38736962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Value of combining biologics with methotrexate for treatment of psoriatic arthritis-questions remain].
    Dauth S; Köhm M; Rossmanith T; Herrmann E; Lehn A; Burkhardt H; Behrens F
    Z Rheumatol; 2018 Nov; 77(9):808-814. PubMed ID: 30203153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics.
    Ritchlin CT; Stahle M; Poulin Y; Bagel J; Chakravarty SD; Kafka S; Srivastava B; Langholff W; Gottlieb AB
    BMC Rheumatol; 2019; 3():52. PubMed ID: 31799498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States.
    Curtis JR; Zhang J; Xie F; Beukelman T; Chen L; Fernandes J; Ginsberg S; Spettell C; Yun H; Saag KG; Schiff M
    Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1604-11. PubMed ID: 24942466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate.
    van Mens LJJ; de Jong HM; Fluri I; Nurmohamed MT; van de Sande MGH; Kok M; van Kuijk AWR; Baeten D
    Ann Rheum Dis; 2019 May; 78(5):610-616. PubMed ID: 30808625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System.
    Penso L; Bergqvist C; Meyer A; Herlemont P; Weill A; Zureik M; Dray-Spira R; Sbidian E
    Arthritis Rheumatol; 2022 Feb; 74(2):244-252. PubMed ID: 34279061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis.
    Betts KA; Griffith J; Friedman A; Zhou ZY; Signorovitch JE; Ganguli A
    Curr Med Res Opin; 2016; 32(4):721-9. PubMed ID: 26743448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does concomitant methotrexate confer clinical benefits in patients treated with prior biologic therapy? Analysis of data from a noninterventional study of rheumatoid arthritis patients initiating treatment with adalimumab.
    Schmalzing M; Behrens F; Schwaneck EC; Koehm M; Greger G; Gnann H; Burkhardt H; Tony HP
    Medicine (Baltimore); 2020 May; 99(19):e20201. PubMed ID: 32384515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United States.
    Lee J; Pelkey R; Gubitosa J; Henrick MF; Ganz ML
    Am Health Drug Benefits; 2017 Feb; 10(1):42-49. PubMed ID: 28465768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines.
    Busger Op Vollenbroek FTM; Doggen CJM; Janssens RWA; Bernelot Moens HJ
    PLoS One; 2018; 13(3):e0194401. PubMed ID: 29570708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis.
    Vieira-Sousa E; Alves P; Rodrigues AM; Teixeira F; Tavares-Costa J; Bernardo A; Pimenta S; Pimentel-Santos FM; Gomes JL; Aguiar R; Pinto P; Videira T; Catita C; Santos H; Borges J; Sequeira G; Ribeiro C; Teixeira L; Ávila-Ribeiro P; Martins FM; Canhão H; McInnes IB; Ribeiro RM; Fonseca JE
    Ann Rheum Dis; 2020 Apr; 79(4):490-498. PubMed ID: 32193187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.